Breaking Boundaries: Immunotherapy for Myeloid Malignancies.
Tatyana GavrilovaEduard SchulzAlain MinaPublished in: Cancers (2024)
Immunotherapy has revolutionized the treatment of myeloid oncologic diseases, particularly for patients resistant to chemotherapy or ineligible for allogeneic stem cell transplantation due to age or fitness constraints. As our understanding of the immunopathogenesis of myeloid malignancies expands, so too do the treatment options available to patients. Immunotherapy in myeloid malignancies, however, faces numerous challenges due to the dynamic nature of the disease, immune dysregulation, and the development of immune evasion mechanisms. This review outlines the progress made in the field of immunotherapy for myeloid malignancies, addresses its challenges, and provides insights into future directions in the field.
Keyphrases
- stem cell transplantation
- bone marrow
- end stage renal disease
- dendritic cells
- acute myeloid leukemia
- ejection fraction
- chronic kidney disease
- newly diagnosed
- high dose
- prostate cancer
- physical activity
- low dose
- immune response
- patient reported outcomes
- body composition
- radiation therapy
- current status
- hematopoietic stem cell
- replacement therapy